Skip to main content
  • Register
  • Help
  • Contact us

Aurinia Pharmaceuticals Inc (AUP) NPV

Sell:15.00 CAD Buy:15.03 CAD Change: 2.73 CAD (18.16%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:15.00 CAD
Buy:15.03 CAD
Change: 2.73 CAD (18.16%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:15.00 CAD
Buy:15.03 CAD
Change: 2.73 CAD (18.16%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. It is developing voclosporin in multiple indications. Voclosporin is an investigational therapy. It is developing voclosporin for the treatment of lupus nephritis (LN) and other proteinuric diseases. It is also advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Voclosporin is a calcineurin inhibitor (CNI). By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney.

Contact details

1203-4464 Markham St
V8Z 7X8
+1 (250) 7084272

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
1.93 billion CAD
Shares in issue:
128.12 million
Toronto Stock Exchange
Canadian dollars

Key personnel

  • George Milne
    Independent Chairman of the Board
  • Peter Greenleaf
    President, Chief Executive Officer, Director
  • Dennis Bourgeault
    Chief Financial Officer
  • Michael Martin
    Chief Operating Officer
  • Stephen Robertson
    Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
  • Maxwell Donley
    Executive Vice President, Internal Operations & Strategy
  • Robert Huizinga
    Executive Vice President - Corporate Development
  • Glenn Schulman
    Senior Vice President - Corporate Communications and Investor Relations
  • Neil Solomons
    Chief Marketing Officer
  • Fran Lynch
    Vice President of Sales

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.